A recent study reveals that individuals who discontinue popular GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who halt traditional diet and exercise programs.
Research printed in a prominent health publication demonstrates that while obese people can lose substantial amounts of their body weight while using the jabs, the mass comes back at an average rate of nearly a kilo each month once they quit.
"Users purchasing these treatments must be cognizant of the risk of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb.
Such speed of regain suggests a return to starting mass within about a year and a half.
Comparing Treatments
The research, which looked at dozens of studies involving thousands of participants, compared the results of these new drugs with older methods.
Scientists emphasize that individuals who lose weight through dieting usually have a less rapid weight regain—perhaps 100 grams monthly—post-intervention.
The Reason for the Fast Regain
Experts believe the way of the jabs is key to understanding the heightened rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels several times higher than normal may cause the body to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement leads to hunger is no longer kept in check, making overeating a significant risk."
A Chronic Disease?
Medical guidelines suggest the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts say that, due to the high risk of weight regain, the treatment is often life-long.
This perspective is reinforced by pharmaceutical companies, who note that the results "underscore the chronic nature of obesity," comparing it to managing conditions like hypertension.
User Testimonies
Individuals who have stopped the medication describe a sudden return of cravings.
"It was like a trigger activating and you're instantly ravenous," described an individual.
The struggle is compounded if patients have not adopted lasting dietary or behavioural modifications during therapy.
Significant Interest
Survey data suggest that millions of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Adoption is more common among women than men.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Ultimately, experts emphasize that while these medications are powerful agents for weight loss, they are not a magic fix and long-term success hinges on combined lifestyle support.
